BioSpace News Archive

Investments towards promotion of fertility treatment services aimed towards international clients is likely to remain key to growth strategies in terms of sales in a fairly competitive industry.

IRRAS, a global healthcare company with a comprehensive portfolio of innovative products for neurocritical care, announced that company management will present at the Swedish Investment Bank Redeye on March 30 at 4:00 pm-5:00pm CET.

Unither Pharmaceuticals, the Blow-Fill-Seal worldwide leader, provides diagnostic companies with capacity solutions and innovative technologies for their testing kits.

A number of studies have shown that human coronaviruses, including SARS-CoV-2 which causes COVID-19, appear to attack neurons and the nervous system in vulnerable populations.

Cleveland Clinic cardiac surgery expertise is now accessible to eligible Eli Lilly and Company employees, retirees and their family members through the Cleveland Clinic Cardiac Concierge Program, in collaboration with Anthem Blue Cross and Blue Shield and its affiliated health plans.

Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the initiation of patient dosing in its Phase 1 clinical trial to evaluate ANK-700 for the treatment of people with relapsing remitting multiple sclerosis (RRMS).

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured an extension to its Schedule I U.S. Drug Enforcement Agency (DEA) license that will allow the Company to conduct research on psychedelics-based pharmaceuticals

Neogen Corporation announced that its revenues for the third quarter of its 2021 fiscal year, which ended Feb. 28, were $116,709,000, up 17% from the previous year’s third quarter revenues of $99,869,000.

Universe Pharmaceuticals INC (the “Company”), a pharmaceutical producer and distributor in China, today announced the pricing of its initial public offering (“Offering”) of 5,000,000 ordinary shares at a public offering price of US$5.00 per ordinary share.

New Rhein Healthcare Investors announced that it has agreed to sell its 60% stake in Softhale NV to Sino Biopharmaceutical Limited for USD 110 million upfront payment plus a profit share.